Program Related Investment (2021)

Gerrit Meijer, MD, PhD, the Netherlands Cancer Institute

CRCbioscreen is a company based in the Netherlands co-founded by Gerrit Meijer, who leads the Translational Gastrointestinal Oncology group at the Netherlands Cancer Institute. For over a decade this group has had a leading role in developing new diagnostic tests for early detection of colorectal cancer, as well as studying the progression of precancerous lesions of the large intestine into tumors. CRCbioscreen is running a prospective screening trial that currently is being conducted in over 13,000 participants in the Dutch national colorectal cancer screening program. The company’s new screening test for colorectal cancer aims to replace classical FIT testing by incorporating novel biomarkers discovered in the Meijer lab to improve detection of early-stage tumors.